LMDX - LumiraDx rapid COVID-19 test gets WHO emergency use listing

LumiraDx (NASDAQ:LMDX) said it received the World Health Organization's (WHO) Emergency Use Listing (EUL) for its rapid COVID-19 antigen assay LumiraDx SARS-CoV-2 Ag Test. The London-based company said that in in studies the test showed 95% positive agreement versus RT-PCR in patients tested within 12 days of the onset of symptoms. The test utilizes nasal swab specimens. Used with the LumiraDx multi-assay platform, the test provides rapid results at the point of care. LumiraDx noted that through a collaboration with the Bill and Melinda Gates Foundation, it has distributed 5K Platforms in 49 African countries.

For further details see:

LumiraDx rapid COVID-19 test gets WHO emergency use listing